Noxafil (posaconazole), an anti- fungal agent may be better than other anti-fungals in helping cancer patients that have GVHD.
GVHD, graft-versus host disease, is a potential complication that can happen after a stem cell transplant. What is really happening is that the new stem cells given from a donor are now giving the patient a chance to build a new immune system--hopefully one that will give a cure. The foreign immune system can begin to attack the cancer patients body that received the transplant. Just like your immune system might reject a heart transplant, the new immune system is seeing the organs of the body as foreign and attack.
To combat this from happening the patients are usually given agents that suppress the immune system. This however, can then cause infections that can quickly develop into a life threatening situation. Researchers are continuing to look for ways to combat the infections that arise.
Noxafil was compared to Diflucan in a study of 600 patients with GVHD who were also receiving therapy to suppress their immune system. The anti-fungal agent that won out was Noxafil for the prevention of fungal infections.
Graft-versus-host disease (GvHD) is a complication that can occur after a stem cell transplant. GvHD occurs when infection-fighting cells from the donor recognize the patient's body as being different or foreign. These infection-fighting cells then attack tissues in the patient's body just as if they were attacking an infection. GvHD is often treated with steroids, though this does not always work. GvHD is a serious condition with a high death rate so researchers are constantly evaluating new ways to treat it or reduce the symptoms.
